Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Cancer treatment and management for elderly patients 80 years of age or older with malignant solid tumors.

Matsubayashi M, Oshita F, Kawata N, Yanagibashi T, Tanaka S, Hao Y, Kurakami Y, Iwabuchi K, Kunishi Y, Ohta M, Nakamura Y, Yoshie K.

J Exp Ther Oncol. 2017 Nov;12(2):143-149.

PMID:
29161783
2.

Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer.

Murakami S, Saito H, Kondo T, Ito H, Oshita F, Yamada K.

Cancer Chemother Pharmacol. 2018 Jan;81(1):81-87. doi: 10.1007/s00280-017-3460-0. Epub 2017 Nov 7.

PMID:
29116379
3.

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K.

J Clin Oncol. 2017 Nov 10;35(32):3662-3670. doi: 10.1200/JCO.2017.72.7297. Epub 2017 Sep 13.

PMID:
28902534
4.

Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).

Sekine I, Harada H, Yamamoto N, Wakabayashi M, Murakami H, Goto K, Nogami N, Seto T, Oshita F, Okamoto H, Tanaka H, Tamura T, Ishikura S, Ohe Y.

Lung Cancer. 2017 Jun;108:232-237. doi: 10.1016/j.lungcan.2017.04.002. Epub 2017 Apr 4.

PMID:
28625642
5.

Severe human parechovirus type 3 infection in adults associated with gastroenteritis in their children.

Tanaka S, Kunishi Y, Ota M, Ono A, Kanno N, Kurakami Y, Yanagibashi T, Matsubayashi M, Hao Y, Iwabuchi K, Oshita F, Yoshie K, Kato Y.

Infect Dis (Lond). 2017 Oct;49(10):772-774. doi: 10.1080/23744235.2017.1323347. Epub 2017 May 12. No abstract available.

PMID:
28498019
6.
7.

Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.

Oshita F, Kasajima R, Miyagi Y.

J Exp Ther Oncol. 2016 Jul;11(3):189-194.

PMID:
28471124
8.

Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.

Nishii T, Yokose T, Miyagi Y, Daigo Y, Isaka T, Furumoto H, Ito H, Murakami S, Kondo T, Saito H, Oshita F, Yamada K, Matsukuma S, Nakayama H, Masuda M.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e204-e211. doi: 10.1111/ajco.12512. Epub 2016 Jun 28.

PMID:
27349355
9.

Relationship between phosphorylation of sperm-specific antigen and prognosis of lung adenocarcinoma.

Okayama A, Kimura Y, Miyagi Y, Oshima T, Oshita F, Ito H, Nakayama H, Nagashima T, Rino Y, Masuda M, Ryo A, Hirano H.

J Proteomics. 2016 Apr 29;139:60-6. doi: 10.1016/j.jprot.2016.03.005. Epub 2016 Mar 3.

PMID:
26947549
10.

Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.

Yamada K, Saito H, Kondo T, Murakami S, Masuda N, Yamamoto M, Igawa S, Katono K, Takiguchi Y, Iwasawa S, Kurimoto R, Okamoto H, Shimokawa T, Hosomi Y, Takagi Y, Kishi K, Ohba M, Oshita F, Watanabe K.

Anticancer Res. 2015 Dec;35(12):6705-11.

PMID:
26637886
11.

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.

Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, Sakamoto T, Miura Y, Yomota M, Satoh A, Kunitoh H, Sakamaki K, Shibuya M, Watanabe K.

BMC Cancer. 2015 Oct 19;15:740. doi: 10.1186/s12885-015-1756-1.

12.

Identification of Tyrosine-Phosphorylated Proteins Upregulated during Epithelial-Mesenchymal Transition Induced with TGF-β.

Okayama A, Miyagi Y, Oshita F, Ito H, Nakayama H, Nishi M, Kurata Y, Kimura Y, Ryo A, Hirano H.

J Proteome Res. 2015 Oct 2;14(10):4127-36. doi: 10.1021/acs.jproteome.5b00082. Epub 2015 Aug 28.

PMID:
26216473
13.

Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma.

Watanabe H, Saito H, Yokose T, Sakuma Y, Murakami S, Kondo T, Oshita F, Ito H, Nakayama H, Yamada K, Iwazaki M.

Ann Thorac Surg. 2015 Mar;99(3):975-81. doi: 10.1016/j.athoracsur.2014.10.065. Epub 2015 Jan 24.

PMID:
25624054
14.

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.

Nishii T, Yokose T, Miyagi Y, Daigo Y, Ito H, Isaka T, Imai K, Murakami S, Kondo T, Saito H, Oshita F, Yamada K, Matsukuma S, Tsuboi M, Nakayama H, Masuda M.

BMC Cancer. 2014 Aug 25;14:610. doi: 10.1186/1471-2407-14-610.

15.

Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy.

Harada T, Saito H, Karino F, Isaka T, Murakami S, Kondo T, Oshita F, Miyagi Y, Yamada K.

Mol Clin Oncol. 2014 Sep;2(5):737-743. Epub 2014 Jun 6.

16.

Proteomic analysis of proteins related to prognosis of lung adenocarcinoma.

Okayama A, Miyagi Y, Oshita F, Nishi M, Nakamura Y, Nagashima Y, Akimoto K, Ryo A, Hirano H.

J Proteome Res. 2014 Nov 7;13(11):4686-94. doi: 10.1021/pr4012969. Epub 2014 Jul 8.

PMID:
25004236
17.

A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).

Kenmotsu H, Niho S, Ito T, Ishikawa Y, Noguchi M, Tada H, Sekine I, Watanabe S, Yoshimura M, Yamamoto N, Oshita F, Kubota K, Nagai K.

Lung Cancer. 2014 Jun;84(3):254-8. doi: 10.1016/j.lungcan.2014.03.007. Epub 2014 Mar 13.

PMID:
24679951
18.

Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer.

Oshita F, Murakami S, Kondo T, Saito H, Yamada K.

J Exp Ther Oncol. 2013;10(3):203-8.

PMID:
24416995
19.

¹⁸F-fluorodeoxyglucose uptake on positron emission tomography in mucinous adenocarcinoma.

Murakami S, Saito H, Karino F, Kondo T, Oshita F, Ito H, Nakayama H, Yokose T, Yamada K.

Eur J Radiol. 2013 Nov;82(11):e721-5. doi: 10.1016/j.ejrad.2013.07.028. Epub 2013 Aug 12.

PMID:
23988690
20.

Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809.

Niho S, Ikeda N, Michimae H, Suzuki K, Sakai H, Kaburagi T, Minato K, Kato T, Okamoto H, Seto T, Hosomi Y, Shimizu K, Oshita F, Kunitoh H, Tsuboi M, Takeuchi M, Watanabe K.

Br J Cancer. 2013 Aug 6;109(3):545-51. doi: 10.1038/bjc.2013.378. Epub 2013 Jul 18.

21.

Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.

Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H, Nagai K.

J Thorac Oncol. 2013 Jul;8(7):980-4. doi: 10.1097/JTO.0b013e31828f6989.

22.

Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy.

Murakami S, Saito H, Ohe M, Kondo T, Oshita F, Yamada K.

Intern Med. 2013;52(5):589-91. Epub 2013 Mar 1.

23.

Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.

Murakami S, Oshita F, Sugiura M, Kondo T, Saito H, Yamada K.

Cancer Chemother Pharmacol. 2013 Mar;71(3):705-11. doi: 10.1007/s00280-012-2061-1. Epub 2013 Jan 18.

PMID:
23328865
24.

Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification.

Honda T, Kondo T, Murakami S, Saito H, Oshita F, Ito H, Tsuboi M, Nakayama H, Yokose T, Kameda Y, Isobe T, Yamada K.

Clin Radiol. 2013 Jan;68(1):e21-6. doi: 10.1016/j.crad.2012.09.002. Epub 2012 Nov 10.

PMID:
23146553
25.

Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.

Oshita F, Sugiura M, Murakami S, Kondo T, Saito H, Yamada K.

Cancer Chemother Pharmacol. 2013 Feb;71(2):345-50. doi: 10.1007/s00280-012-2011-y. Epub 2012 Nov 3.

PMID:
23124649
26.

Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.

Ohe M, Oshita F, Kenmotsu Y, Sugiura M, Murakami S, Kondo T, Saito H, Yamada K.

J Exp Ther Oncol. 2012;10(1):65-9.

PMID:
22946345
27.

Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.

Kenmotsu Y, Oshita F, Sugiura M, Murakami S, Kondo T, Saito H, Yamada K.

Anticancer Res. 2012 Apr;32(4):1453-6.

PMID:
22493385
28.

Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.

Saito H, Murakami S, Kondo T, Oshita F, Noda K, Yamada K.

Onkologie. 2012;35(1-2):18-22. doi: 10.1159/000335736. Epub 2012 Jan 13.

29.

Plasma free amino acid profiling of five types of cancer patients and its application for early detection.

Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, Saruki N, Bando E, Kimura H, Imamura F, Moriyama M, Ikeda I, Chiba A, Oshita F, Imaizumi A, Yamamoto H, Miyano H, Horimoto K, Tochikubo O, Mitsushima T, Yamakado M, Okamoto N.

PLoS One. 2011;6(9):e24143. doi: 10.1371/journal.pone.0024143. Epub 2011 Sep 7.

30.

Growth rate of lung cancer recognized as small solid nodule on initial CT findings.

Mikita K, Saito H, Sakuma Y, Kondo T, Honda T, Murakami S, Oshita F, Ito H, Tsuboi M, Nakayama H, Yokose T, Kameda Y, Noda K, Yamada K.

Eur J Radiol. 2012 Apr;81(4):e548-53. doi: 10.1016/j.ejrad.2011.06.032. Epub 2011 Jul 26.

PMID:
21794996
31.

Prognostic value of preoperative FDG-PET in stage IA lung adenocarcinoma.

Murakami S, Saito H, Sakuma Y, Kondo T, Oshita F, Ito H, Tsuboi M, Hasegawa C, Yokose T, Kameda Y, Nakayama H, Yamada K.

Eur J Radiol. 2012 Aug;81(8):1891-5. doi: 10.1016/j.ejrad.2011.04.007. Epub 2011 May 4.

PMID:
21546177
32.

Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.

Oshita F, Miyagi Y, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yokose T, Kameda Y, Sakuma Y, Obata M, Yamada K.

J Exp Ther Oncol. 2010;8(4):313-9.

PMID:
21222363
33.

Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.

Oshita F, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yamada K.

J Thorac Oncol. 2011 Jan;6(1):128-31. doi: 10.1097/JTO.0b013e3181ccb3a9.

34.

Comparison of thin-section CT and pathological findings in small solid-density type pulmonary adenocarcinoma: prognostic factors from CT findings.

Ikehara M, Saito H, Kondo T, Murakami S, Ito H, Tsuboi M, Oshita F, Noda K, Nakayama H, Yokose T, Kameda Y, Yamada K.

Eur J Radiol. 2012 Jan;81(1):189-94. doi: 10.1016/j.ejrad.2010.09.026. Epub 2010 Oct 20.

PMID:
20965677
35.

Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.

Oshita F, Ohe M, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yamashita K, Nakayama Y, Yamada K.

Br J Cancer. 2010 Oct 26;103(9):1325-30. doi: 10.1038/sj.bjc.6605875. Epub 2010 Oct 12.

36.

Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer.

Oshita F, Morita A, Ito H, Kameda Y, Tsuchiya E, Asai S, Miyagi Y.

Oncol Rep. 2010 Sep;24(3):637-45.

PMID:
20664968
37.

Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.

Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K, Yamada K.

Lung Cancer. 2010 Sep;69(3):361-4. doi: 10.1016/j.lungcan.2010.05.019. Epub 2010 Jun 17.

PMID:
20659620
38.

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.

Br J Cancer. 2010 Aug 10;103(4):517-23. doi: 10.1038/sj.bjc.6605786. Epub 2010 Jul 13.

39.

Correlations between thin-section CT findings, histopathological and clinical findings of small pulmonary adenocarcinomas.

Saito H, Kameda Y, Masui K, Murakami S, Kondo T, Ito H, Oshita F, Tsuboi M, Yokose T, Noda K, Nakayama H, Yamada K.

Lung Cancer. 2011 Feb;71(2):137-43. doi: 10.1016/j.lungcan.2010.04.018. Epub 2010 Jun 8.

PMID:
20566399
40.

Correlations of thin-section computed tomographic, histopathological, and clinical findings of adenocarcinoma with a bubblelike appearance.

Kojima Y, Saito H, Sakuma Y, Kondo T, Ito H, Tsuboi M, Oshita F, Nakayama H, Yokose T, Kameda Y, Noda K, Yamada K.

J Comput Assist Tomogr. 2010 May-Jun;34(3):413-7. doi: 10.1097/RCT.0b013e3181d275b6.

PMID:
20498546
41.

Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size.

Murakami S, Saito H, Sakuma Y, Mizutani Y, Ishikawa Y, Kondou T, Oshita F, Yokose T, Kameda Y, Suga Y, Ito H, Tsuboi M, Nakayama H, Noda K, Yamada K.

Eur J Radiol. 2010 Aug;75(2):e62-6. doi: 10.1016/j.ejrad.2009.11.020. Epub 2009 Dec 14.

PMID:
20005653
42.

Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.

Oshita F, Saito H, Murakami S, Kondo T, Yamada K.

Am J Clin Oncol. 2010 Feb;33(1):66-9. doi: 10.1097/COC.0b013e31819ccc6d.

PMID:
19786849
43.

Initial findings and progression of lung adenocarcinoma on serial computed tomography scans.

Saito H, Yamada K, Hamanaka N, Oshita F, Ito H, Nakayama H, Yokose T, Kameda Y, Noda K.

J Comput Assist Tomogr. 2009 Jan-Feb;33(1):42-8. doi: 10.1097/RCT.0b013e3181633509.

PMID:
19188783
44.

A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size.

Sakuma Y, Okamoto N, Saito H, Yamada K, Yokose T, Kiyoshima M, Asato Y, Amemiya R, Saitoh H, Matsukuma S, Yoshihara M, Nakamura Y, Oshita F, Ito H, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y.

Lung Cancer. 2009 Jul;65(1):85-90. doi: 10.1016/j.lungcan.2008.10.011. Epub 2008 Nov 22.

PMID:
19027984
45.

Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer.

Oshita F, Saito H, Yamada K.

Oncology. 2008;74(1-2):7-11. doi: 10.1159/000138350. Epub 2008 Jun 9.

PMID:
18536524
46.

Prognosis of small adenocarcinoma of the lung based on thin-section computed tomography and pathological preparations.

Ikehara M, Saito H, Yamada K, Oshita F, Noda K, Nakayama H, Masui K, Kameda Y, Komase Y, Miyazawa T.

J Comput Assist Tomogr. 2008 May-Jun;32(3):426-31. doi: 10.1097/RCT.0b013e31811edc93.

PMID:
18520551
47.

Prognostic significance of thin-section CT scan findings in small-sized lung adenocarcinoma.

Hashizume T, Yamada K, Okamoto N, Saito H, Oshita F, Kato Y, Ito H, Nakayama H, Kameda Y, Noda K.

Chest. 2008 Feb;133(2):441-7. Epub 2007 Dec 10.

PMID:
18071015
48.

Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.

Oshita F, Yamada K, Saito H, Noda K.

Cancer Chemother Pharmacol. 2008 Aug;62(3):465-70. Epub 2007 Oct 25.

PMID:
17960380
49.

Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging.

Nakayama H, Yamada K, Saito H, Oshita F, Ito H, Kameda Y, Noda K.

Ann Thorac Surg. 2007 Nov;84(5):1675-9.

PMID:
17954084
50.

Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.

Oshita F, Saito H, Yamada K, Noda K.

Am J Clin Oncol. 2007 Aug;30(4):358-60.

PMID:
17762435

Supplemental Content

Loading ...
Support Center